Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for detecting deficient cellular membrane tightly bound magnesium for disease diagnoses

a technology of tightly bound magnesium and cellular membrane, which is applied in the field of methods and diagnostic kits for detecting the defect of cellular membrane magnesium binding, can solve the problems of end-organ damage, high risk of developing significant complications, and death complications

Inactive Publication Date: 2007-06-14
MAGNESIUM DIAGNOSTICS
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent is about methods for detecting physiological disorders in humans, specifically those related to magnesium levels and the breakdown of certain proteins. These methods involve measuring the levels of certain peptides in blood plasma. The patent proposes that these peptides are indicators of these disorders and can help with their diagnosis and treatment.

Problems solved by technology

It is of common occurrence, asymptomatic, readily detectable, and often leads to lethal complications if not treated.
Even individuals with relatively mild disease—those individuals without evidence of end-organ damage—if left untreated for 7 to 10 years have a high risk of developing significant complications, and more than 50 percent of them will ultimately experience end-organ damage related to hypertension.
Thus, even in its mild forms, hypertension can be a lethal disease, if left untreated.
Such complications include atherosclerosis, the risk for which is greatest in poorly controlled patients.
However, applicant has observed the highly frequent occurrence of the magnesium binding defect in the erythrocyte membranes of mildly affected Type 2 diabetics.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0018] Applicant quantified the magnesium contents of the several anatomical compartments of whole blood from some essential hypertension patients and normotensive control subjects and discovered several differences. The most noteworthy difference was the decreased levels of magnesium firmly bound to the erythrocyte membranes of the hypertensive patients. The magnitude of this previously unknown defect correlated positively with the magnitude of the decreased concentration of intracellular magnesium which in turn correlated positively with the average blood pressures of the patients. Further, another novel observation was that this magnesium binding defect was corrected by incubating the erythrocytes from the hypertensive patients with blood plasma from the control subjects (Mattingly M T, Brezezinski W A, Wells I C, Clin. Exper. Hypertension-Theory and Practice A13: 65-82 (1991)).

[0019] This investigation was extended to include two strains of genetic, sodium-sensitive, hypertensi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
systolic blood pressureaaaaaaaaaa
arterial pressureaaaaaaaaaa
pressureaaaaaaaaaa
Login to View More

Abstract

This invention relates to methods for detecting the deficiency of magnesium tightly bound to cellular membranes, i.e., magnesium binding defect, which deficiency is associated with certain abnormal physiological states, e.g., salt-sensitive essential hypertension or Type 2 diabetes mellitus.

Description

CROSS REFERENCE [0001] This application is a continuation of U.S. patent application having Ser. No. 10 / 053,669, filed Jan. 24, 2002, which is a continuation of U.S. patent application having Ser. No. 09 / 265,690, filed Mar. 10, 1999, the disclosures of which are incorporated in full herein.BACKGROUND OF THE INVENTION [0002] 1. Field of Invention [0003] This invention relates to methods and diagnostic kits for detecting the cellular membrane magnesium binding defect, which deficiency is critically associated with certain abnormal physiological states, e.g. sodium-sensitive essential hypertension and type 2 insulin-resistant diabetes mellitus. [0004] 2. Description of the Prior Art [0005] Elevated arterial pressure, namely hypertension, is probably among the most important public health problems in developed countries. It is of common occurrence, asymptomatic, readily detectable, and often leads to lethal complications if not treated. Although there are exceptions, most untreated adul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/567G01N33/53G01N33/68
CPCG01N33/6893G01N2800/042G01N2800/321Y10S514/866
Inventor WELLS, IBERT C.
Owner MAGNESIUM DIAGNOSTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products